<DOC>
	<DOCNO>NCT00146211</DOCNO>
	<brief_summary>This study design determine effect 2 gram/day ethyl-EPA motor ( movement ) sign symptoms Huntington disease .</brief_summary>
	<brief_title>TREND-HD - A Trial Ethyl-EPA ( Miraxion™ ) Treating Mild Moderate Huntington 's Disease</brief_title>
	<detailed_description>Multi-center , double blind , placebo-controlled study parallel group outpatient early , symptomatic Huntington 's disease . Participants randomize receive 1 gram twice daily ( 2 gram/day total daily dose ) active study drug placebo . The 6-month placebo-controlled phase followed subsequent 6-month open-label extension phase subject receive 1 gram twice daily ( 2 grams/day total daily dose ) active study drug .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Clinical feature Huntington 's disease ( HD ) confirmatory family history HD , and/or CAG repeat expansion great equal 36 Ambulatory , require skilled nursing care ( total functional capacity [ TFC ] great equal 7 ) Chorea score least 2 one extremity ( UHDRS ) Maximal dystonia less equal 2 maximal bradykinesia less equal 2 35 year age old either gender Must stable dosage noncompetitive NMDA receptor antagonist , and/or antiepileptic medication 60 day prior baseline Females childbearing potential must use adequate birth control History establish diagnosis tardive dyskinesia Clinical evidence unstable medical psychiatric illness Clinically significant active unstable psychotic disease ( hallucination delusion ) Major depression ( Beck Depression Inventory [ BDI ] II Score great 20 ) Screening Visit Suicidal ideation ( BDIII item 9 great equal 2 ) Screening Visit History clinically significant substance abuse within 12 month Baseline Visit Pregnant/lactating woman Participation drug study within 60 day prior Baseline Visit Previous participation investigational study ethylEPA ( Miraxion™ ) Use aspirin daily dosage great 325 mg/day Exclusionary Drugs ( within 6 month Baseline Visit ) : Depot neuroleptic Exclusionary Drugs ( within 60 day Baseline Visit ) : Omega3 supplementation , tetrabenazine reserpine , high dose and/or variable dose oral antipsychotic medication , steroid ( topical ) , selenium supplement great 55 mcg/day , lithium , benzodiazepine ( except low dose ) , anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Trial</keyword>
	<keyword>ethyl-EPA</keyword>
	<keyword>Miraxion™</keyword>
	<keyword>treat</keyword>
	<keyword>mild</keyword>
	<keyword>moderate</keyword>
	<keyword>Huntington 's</keyword>
</DOC>